The Problem LINX™ Was Never Built to Solve

When LINX™ first came on the market, it had real appeal: a small ring of magnetic beads placed around the lower esophageal sphincter, done laparoscopically, reversible if needed. For a while, many of my patients came in asking about it. That has largely stopped, and I think it’s worth explaining why the enthusiasm has faded. LINX™, by design, only addresses part of what actually causes most reflux. And at the same time that gap has become more apparent, the device itself has been quietly retreating from the global market.

Reflux Isn’t Mainly a “Weak Sphincter” Problem

For decades, the working theory of GERD was simple: the lower esophageal sphincter (LES) is too weak, so acid leaks past it. That theory drove a lot of early surgical thinking, including the initial appeal of any device that promises to “tighten” the sphincter.

But research going back to the 1980s changed that picture substantially. Most reflux episodes, in both healthy people and GERD patients, aren’t caused by a chronically weak LES at all. They’re caused by transient LES relaxations, or TLESRs: brief, spontaneous episodes where the LES drops to zero pressure for 10 to 45 seconds, unrelated to swallowing. TLESRs are actually a normal reflex (not reflux), part of how the stomach vents gas after a meal, triggered by distention of the gastric fundus. Healthy people have them 2 to 6 times an hour. GERD patients have them more often, 3 to 8 times an hour, and are more likely to reflux acid during each one.

That distinction matters enormously for how we think about surgical treatment.

What LINX™ Actually Does, and Doesn’t Do

LINX™ is marketed as a “magnetic sphincter augmentation” device, but in my view that name is a misnomer. As I’ll explain below, the main reason LINX™ fails to stop acid reflux is precisely that it does not augment the sphincter. What it does is make the esophageal wall around the LES harder to open. Devices that work this way are limited by a hard ceiling, dysphagia. Any device that works by making the esophagus harder to open will, at some point, make it hard enough to open that it interferes with normal swallowing. That’s not a flaw specific to LINX™; it’s a constraint built into the entire concept of sphincter augmentation as a strategy.

Nissen fundoplication is not a sphincter augmentation procedure, and that distinction matters. It doesn’t work by adding resistance around the LES at all. Its exact mechanism of action is still not fully understood, but it helps to separate what it does anatomically from what it does physiologically. Anatomically, two things are restored: the hiatal hernia repair restores the intra-abdominal esophagus, and the fundoplication restores the angle of His. That is as far as the anatomy goes. The rest of its effects are physiological. A fundoplication decreases the frequency of TLESRs and improves gastric emptying. Because it isn’t a sphincter augmentation procedure, it isn’t bound by the same dysphagia ceiling that limits every device in that category, including LINX™.

Despite the name, LINX™ doesn’t actually augment LES tone. The muscle tone of the sphincter itself is unchanged after the ring is placed around it. What changes is the tissue around it: scar tissue forms around the beads, and that scar decreases the wall compliance of the esophagus at the LES. The wall becomes stiffer and harder to stretch open. That stiffness is what makes swallowing more difficult, and, as I’ll explain below, it does a much better job of blocking food than it does of blocking liquid acid.

But a TLESR isn’t the LES being too weak. It’s the LES being actively, neurally commanded to relax, in response to gastric distention. A magnetic ring around the esophagus doesn’t interrupt that reflex. The stomach still distends, the vagal-mediated relaxation signal still fires, and the LES still opens, magnets and all, because that’s exactly what a TLESR is.

The Real Achilles’ Heel: How LINX™ Actually Fails

Here’s the mechanical problem in more detail, because it explains why LINX™’s failure mode isn’t random. It’s built into how the device works.

To understand why, it helps to know that the LES is unlike any other sphincter in the body. It is not a distinct, palpable ring of muscle. Run a finger through the anal sphincter and you feel a firm muscular ring. Run a finger through the LES and you feel nothing of the kind: it blends seamlessly into the esophageal wall. That is why the LES evaded many anatomists and surgeons early on, and for decades its very existence was debated. It wasn’t until 1956, when researchers at the Mayo Clinic passed pressure sensors through the junction between the esophagus and the stomach, that a zone of high pressure was found there. It was that high-pressure zone on manometry, not anything seen or felt, that pointed to the location of the LES and confirmed that it exists. We now know that the LES is made of two groups of muscle fibers: clasp fibers, which are part of the esophagus’s circular muscle layer, and sling fibers, which are continuous with the oblique muscle of the stomach. Rather than a separate ring, the LES is where the muscle of the esophagus and the muscle of the stomach meet and blend. That is also why a ring placed around it can’t strengthen it the way it might strengthen a discrete muscle. The beads sit around the esophageal wall, and the scar they create stiffens that wall, but the sphincter inside keeps doing exactly what it did before.

Think of what LINX™ creates as a rigid tunnel around the LES. The sphincter muscle inside that tunnel is unchanged, and it still relaxes during every TLESR. When it does, the lumen inside the tunnel opens, leaving an open channel between the stomach and the esophagus, even though the ring of beads hasn’t pulled apart. Liquid acid doesn’t need the wall to stretch to get through; it simply pours up through that channel along the pressure gradient. The device isn’t failing because it’s defective; it’s failing because a TLESR is doing exactly what a TLESR does, inside a tunnel that was never built to stop it.

That is the only explanation I have for one of the most striking numbers in the pivotal FDA trial of LINX™: about 4 in 10 patients still did not have normal esophageal acid exposure a year after surgery. For a procedure meant to treat acid reflux, that is a high failure rate.

Solids are a different story. A bolus of food needs a compliant, stretchable wall to pass through, in either direction. The stiff, scarred tunnel around the LES resists that stretch. That is why LINX™ stops food regurgitation more reliably than it stops heartburn, which is the result of liquid acid reflux. It is also why the same stiffness makes swallowing difficult.

Smaller LINX™ devices are consistently linked to more dysphagia and more device removals, which is why surgeons have moved toward larger sizes. But a 2024 study of more than 600 patients found that going larger did not improve acid control at all. That fits the rigid-tunnel explanation: if the LES still relaxes inside the tunnel during a TLESR, the size of the ring doesn’t matter to liquid acid. Changing the size only changes how hard the tunnel is on food.

This is where a Nissen fundoplication is fundamentally different, not just anatomically but mechanically. A properly performed Nissen wrap is floppy. It doesn’t function by squeezing the lumen shut, and its effectiveness doesn’t depend on how tightly it hugs the esophagus. Instead, beyond restoring the anatomy, fundoplication changes the physiology: it decreases the frequency of TLESRs themselves, rather than just resisting the ones that occur, and it improves gastric emptying. LINX™ has no such effect on TLESR frequency. It can only try to out-muscle each episode as it happens, using a stiffer, less compliant esophageal wall as its only tool. A Nissen fundoplication doesn’t compress the lumen at all, and doesn’t need to. In my own experience at Houston Heartburn and Reflux Center, a properly performed Nissen fundoplication has a dysphagia rate of zero.

That distinction, reducing the reflex versus straining to resist it, is the real reason LINX™ underperforms as a long-term solution, and why its dysphagia problem is baked into the device rather than being a matter of surgical technique.

Here’s the honest truth: we don’t fully understand what drives TLESRs, or why some patients have them far more often than others. What we do know is that LINX™ only does one thing: it stiffens the esophageal wall around the sphincter through scar tissue. It doesn’t reconstruct the antireflux barrier itself.

A Nissen fundoplication does something fundamentally different. The hiatal hernia repair, which closes the diaphragmatic crura, restores the intra-abdominal esophagus. The fundoplication restores the angle of His. Those are the anatomic corrections. On top of them come the physiological effects: fewer TLESRs and better gastric emptying. We may not fully understand every way a Nissen works, but it addresses both the anatomy and the physiology of the barrier rather than just tightening one part of it.

That’s why I don’t offer LINX™ in my practice. When properly performed, for the right patient, a Nissen fundoplication is far more reliable than magnetic sphincter augmentation. As a specialist who has built my practice entirely around foregut and reflux surgery, I hold myself to that standard with every patient I operate on.

LINX™ Is Also Disappearing From the Market

Independent of the mechanism question, there’s a market signal worth patients knowing about. In September 2025, Johnson & Johnson’s Ethicon division began withdrawing LINX™ from markets outside the United States, with sales abroad ending in March 2026. The company described this as a commercial decision, not a safety or efficacy finding.

What makes the timing notable is that this pullback came shortly after the FDA expanded LINX™’s approved use, including an August 2024 labeling change adding patients with Barrett’s esophagus, and growing use in patients with larger hiatal hernias that were originally outside the device’s studied population. So the indication is widening even as the company’s global commercial commitment to the product appears to be narrowing.

What About RefluxStop™?

A newer device, RefluxStop™, received FDA approval in August 2026 after about eight years of use in Europe, and it is sometimes described as the next step after LINX™. It takes a different approach: it does not encircle the esophagus. Instead, it aims to keep the LES in the abdomen and preserve the angle of His, two of the same anatomic goals a Nissen fundoplication achieves. That is a more sensible target than stiffening the esophageal wall.

But in my view, the ultimate test of whether RefluxStop™ works is its effect on TLESRs, the mechanism behind most reflux. Despite eight years of experience in Europe, that has not been studied. The evidence so far rests on symptom scores and pH testing from small series, and its main prospective study enrolled just 50 patients with no comparison group.

And even if RefluxStop™ turns out to reduce TLESRs, a more basic question remains: what advantage would it offer over a properly performed Nissen fundoplication, which already restores the anatomy, reduces TLESRs, improves gastric emptying, and in my experience causes no dysphagia, without leaving a permanent implant behind?

A New Technology, Judged By an Old Standard

There’s a useful framework for thinking about why devices like LINX™ get adopted quickly, and why that speed isn’t the same thing as being right. Neurosurgeon Charles Wilson wrote a widely cited 2006 analysis in the British Medical Journal on how surgeons adopt new technology, and his central point still holds: a new technique spreading fast isn’t evidence that it’s a better one. Wilson observed that surgical innovations tend to catch on when they’re easy to learn, easy to add to existing practice, and appealing to patients, regardless of whether they’ve actually been shown to outperform what’s already being done. He proposed a short set of questions any surgeon should ask before adopting a new technology, and they apply directly here.

Will it improve the quality of care? For LINX™, the honest answer is: not compared with what a properly performed Nissen fundoplication already achieves. Stiffening the esophageal wall around the sphincter is a narrower intervention than reconstructing the antireflux barrier itself, and a narrower mechanism is a hard case to make as an improvement over the established standard.

Is it compatible with what’s already established? Fundoplication has decades of surgical precedent behind it. The wrap-based, one-way-valve approach is the existing “social pattern” of antireflux surgery, to borrow Wilson’s phrase. LINX™ doesn’t build on that approach; it substitutes a device-based fix for a different, narrower mechanism entirely. That’s not compatibility, that’s a competing model with a weaker evidence base.

Have all the barriers to adoption been identified? This is where LINX™’s track record is most telling. Dysphagia isn’t a rare or hypothetical risk flagged in a first-in-human study. It’s a well-documented, recurring complication after wide clinical use, and it’s a direct consequence of the sphincter augmentation category LINX™ belongs to. By Wilson’s standard, a technology with an unresolved, structural barrier to adoption hasn’t cleared the bar in the first place, regardless of how appealing the initial pitch may have been.

Wilson’s larger point was that a surgeon’s skill in performing a procedure is irrelevant if the procedure shouldn’t be offered in the first place. That’s precisely why I don’t offer LINX™: the question isn’t whether it can be done well, it’s whether it should be done at all when a more reliable, better-established alternative exists.

What This Means If You’re Considering Surgery for Reflux

None of this makes LINX™ a reliable option. Beyond the mechanism problem, LINX™ carries its own well-documented downside: dysphagia (difficulty swallowing) is a common complication of the device, and it’s a structural limitation of sphincter augmentation as a category, not a rare or fixable side effect. Between the reliability gap and the dysphagia risk, I don’t see a role for LINX™ in the management of acid reflux.

While I don’t implant LINX™, I do offer LINX™ removal surgery. For patients with persistent dysphagia that hasn’t improved with time or with repeated dilations, removing the device can relieve the swallowing problem. Because removal alone would leave the reflux untreated, I perform a Nissen or Toupet fundoplication during the same operation in which the LINX™ is removed, to control the reflux. If you have a LINX™ and are struggling to swallow, a careful evaluation can show whether removal is the right next step.

Key Clinical Points

• Most reflux is caused by transient LES relaxations (TLESRs), a normal gastric-venting reflex triggered by stomach distention, not simply a chronically weak sphincter
• LINX™ is marketed as “sphincter augmentation,” but that is a misnomer: it does not augment the sphincter, and devices in this category are inherently limited by dysphagia: any device that works by making the esophagus harder to open will eventually make it hard enough to interfere with swallowing
• Nissen fundoplication is not a sphincter augmentation procedure. The hiatal hernia repair restores the intra-abdominal esophagus and the fundoplication restores the angle of His, without relying on compression, so it isn’t bound by that same dysphagia ceiling
• TLESRs occur 2–6 times per hour in healthy people and 3–8 times per hour in GERD patients, and devices like LINX™ do not interrupt this reflex
• LINX™ doesn’t change LES muscle tone; it decreases wall compliance around the LES through scar tissue formation, but doesn’t reconstruct the antireflux barrier, and it carries a well-documented risk of dysphagia
• LINX™ creates a rigid tunnel around the LES, but the LES still relaxes inside it during TLESRs, leaving an open channel for liquid acid. This is the best explanation for why about 4 in 10 patients in the pivotal FDA trial did not normalize esophageal acid exposure, and why LINX™ controls food regurgitation better than heartburn
• Smaller LINX™ devices cause more dysphagia, but larger devices don’t improve acid control, consistent with the LES relaxing inside the tunnel regardless of ring size
• A Nissen fundoplication’s floppy wrap doesn’t depend on lumen compression to work; its physiological effects include decreasing TLESR frequency and improving gastric emptying. LINX™ has no effect on TLESR frequency and can only resist each episode as it happens
• Johnson & Johnson’s Ethicon division began withdrawing LINX™ from markets outside the U.S. in September 2025, officially citing commercial rather than safety reasons, shortly after the FDA expanded its approved U.S. indications in 2024
• RefluxStop™, FDA-approved in August 2026, avoids encircling the esophagus, but its effect on TLESRs, the real test, has not been studied, and its advantage over a properly performed Nissen fundoplication remains unclear
• Dr. Darido does not implant LINX™, but he offers LINX™ removal surgery for patients with persistent dysphagia after the device was placed, with a Nissen or Toupet fundoplication performed during the same operation to control reflux
• A properly performed Nissen fundoplication, for the right patient, remains the most reliable antireflux procedure, because it corrects the anatomy and improves the physiology of the barrier rather than just augmenting one part of it. In my experience at Houston Heartburn and Reflux Center, a properly performed Nissen has a zero dysphagia rate

If you’ve been told LINX™ is your best option without a full workup of how your reflux actually behaves, I’d encourage you to get a second opinion. At Houston Heartburn and Reflux Center, every preoperative evaluation includes the diagnostic testing needed to understand what’s actually driving your reflux, not just where your LES pressure measures.

Elias F. Darido, MD, FACS

Houston Heartburn and Reflux Center

Originally published: August 2026 | Last reviewed: August 2026

References

1. Code CF, Fyke FE Jr, Schlegel JF. The gastroesophageal sphincter in healthy human beings. Gastroenterologia. 1956;86(3):135–150. doi:10.1159/000200544

2. Greene CL, Worrell SG, Patti MG, DeMeester TR. The University of Chicago contribution to the treatment of gastroesophageal reflux disease and its complications: a tribute to David B. Skinner 1935–2003. Ann Surg. 2015;261(3):445–450. doi:10.1097/SLA.0000000000000698

3. Lower esophageal sphincter anatomy and physiology. GI Motility Online. Nature Publishing Group; 2006. https://www.nature.com/gimo/contents/pt1/full/gimo14.html

4. Ganz RA, Peters JH, Horgan S, et al. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med. 2013;368(8):719–727. doi:10.1056/NEJMoa1205544

5. DeMarchi J, et al. Evolution of a novel technology for gastroesophageal reflux disease: a safety perspective of magnetic sphincter augmentation. Dis Esophagus. 2021;34(11):doab036. doi:10.1093/dote/doab036

6. Froiio C, et al. Safety profile of magnetic sphincter augmentation for gastroesophageal reflux disease. Front Surg. 2023;10:1293270. doi:10.3389/fsurg.2023.1293270

7. Ayazi S, Zheng P, Zaidi AH, et al. Magnetic sphincter augmentation and postoperative dysphagia: characterization, clinical risk factors, and management. J Gastrointest Surg. 2020;24(1):39–49. doi:10.1007/s11605-019-04331-9

8. Fatima I, et al. Large-caliber endoscopic balloon dilation in patients with persistent dysphagia after magnetic sphincter augmentation (MSA) is safe and may reduce the need for subsequent dilations and device removal. Surg Endosc. 2026. doi:10.1007/s00464-026-13203-8

9. Sarici IS, et al. Impact of change in sizing protocol on outcome of magnetic sphincter augmentation. Ann Surg. 2025;281(3):454–461. doi:10.1097/SLA.0000000000006249

10. Ayazi S, et al. Measurement of outflow resistance imposed by magnetic sphincter augmentation: defining normal values and clinical implication. Surg Endosc. 2021;35(10):5787–5795. doi:10.1007/s00464-020-08068-4

11. Whooley S. Johnson & Johnson reportedly set to pull Linx reflux management device from OUS markets. MassDevice. September 23, 2025. https://www.massdevice.com/johnson-johnson-pull-linx-ous-markets/

12. Johnson & Johnson MedTech announces labeling amendment of LINX™ Reflux Management System in the U.S. to include patients with Barrett’s esophagus experiencing gastroesophageal reflux disease [press release]. Johnson & Johnson; August 7, 2024. https://www.jnj.com/media-center/press-releases/johnson-johnson-medtech-announces-labeling-amendment-of-linx-reflux-management-system-in-the-u-s-to-include-patients-with-barretts-esophagus-experiencing-gastroesophageal-reflux-disease

13. Harsányi L, Kincses Z, Zehetner J, Altorjay Á. Treating acid reflux without compressing the food passageway: 4-year safety and clinical outcomes with the RefluxStop device in a prospective multicenter study. Surg Endosc. 2024;38(10):6060–6069. doi:10.1007/s00464-024-11114-0

14. FDA approves Implantica’s RefluxStop for GERD as J&J exits non-U.S. markets. MD+DI. August 25, 2026. https://www.mddionline.com/implants/fda-approves-implantica-s-refluxstop-for-gerd-as-j-j-exits-non-u-s-markets

15. Wilson CB. Adoption of new surgical technology. British Medical Journal. 2006;332(7533):112–114. doi:10.1136/bmj.332.7533.112